Publication: Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group
dc.contributor.author | Gürbüz, Mustafa | |
dc.contributor.author | Akkuş, Erman | |
dc.contributor.author | Sakin, Abdullah | |
dc.contributor.author | Urvay, Semiha | |
dc.contributor.author | Demiray, Atike Gökçen | |
dc.contributor.author | Şahin, Süleyman | |
dc.contributor.author | Sakalar, Teoman | |
dc.contributor.author | Erol, Cihan | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.contributor.author | Şahin, Ahmet Bilgehan | |
dc.contributor.author | Çubukcu, Erdem | |
dc.contributor.author | Guven, Deniz Can | |
dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Ergün, Yakup | |
dc.contributor.author | Uncu, Doğan | |
dc.contributor.author | Turhal, Nazim Serdar | |
dc.contributor.author | Uskent, Necdet | |
dc.contributor.author | Çınkır, Havva Yeşil | |
dc.contributor.author | Demir, Atakan | |
dc.contributor.author | Acar, Ramazan | |
dc.contributor.author | Karadurmuş, Nuri | |
dc.contributor.author | Türker, Sema | |
dc.contributor.author | Altınbaş, Mustafa | |
dc.contributor.author | Karaoğlan, Mert | |
dc.contributor.author | Şenler, Filiz Çay | |
dc.contributor.buuauthor | ŞAHİN, AHMET BİLGEHAN | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0002-7846-0870 | |
dc.contributor.orcid | 0000-0002-0070-0889 | |
dc.contributor.researcherid | AAM-4927-2020 | |
dc.contributor.researcherid | JGT-4101-2023 | |
dc.date.accessioned | 2024-06-12T06:13:29Z | |
dc.date.available | 2024-06-12T06:13:29Z | |
dc.date.issued | 2021-01-24 | |
dc.description.abstract | Purpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab +/- capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab +/- capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance +/- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer. | |
dc.identifier.doi | 10.1007/s12029-021-00594-1 | |
dc.identifier.eissn | 1941-6636 | |
dc.identifier.endpage | 288 | |
dc.identifier.issn | 1941-6628 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 282 | |
dc.identifier.uri | https://doi.org/10.1007/s12029-021-00594-1 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s12029-021-00594-1 | |
dc.identifier.uri | https://hdl.handle.net/11452/42022 | |
dc.identifier.volume | 53 | |
dc.identifier.wos | 000614703600001 | |
dc.indexed.wos | WOS.ESCI | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.relation.journal | Journal of Gastrointestinal Cancer | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Phase-ii | |
dc.subject | Combination | |
dc.subject | Adenocarcinoma | |
dc.subject | Multicenter | |
dc.subject | Oxaliplatin | |
dc.subject | Cisplatin | |
dc.subject | HER2 | |
dc.subject | S-1 | |
dc.subject | Gastric cancer | |
dc.subject | Trastuzumab | |
dc.subject | Chemotherapy | |
dc.subject | Maintenance | |
dc.subject | Oncology | |
dc.subject | Gastroenterology & hepatology | |
dc.title | Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 4dc703eb-05b2-4b24-b6ad-dcaca00b36d9 | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication.latestForDiscovery | 4dc703eb-05b2-4b24-b6ad-dcaca00b36d9 |